MedPacto Presents Clinical Data on Pancreatic Cancer Combination Therapy with Baektocept at American Society of Clinical Oncology

MedPacto announced on the 18th that it presented preclinical data on the combination therapy of Betosertib for pancreatic cancer at the 'American Association for Cancer Research 2023 (AACR 2023)'.

MedPacto CI. [Photo by MedPacto]

원본보기 아이콘

From the 14th to the 19th (local time), MedPacto disclosed preclinical data on the combination therapy of Betosertib and 'T1-44', an arginine methyltransferase 5 (PRMT5) protein activity inhibitor, at AACR 2023 held in Orlando, Florida, USA. This study was conducted in collaboration with Professor Nick Lathan of the University of Oxford, UK, who developed the PRMT5 protein inhibitor 'T1-44'. PRMT5 protein, known as an enzyme that promotes cancer growth, is reported to be overexpressed in various cancers including pancreatic cancer.

The research team confirmed the anticancer effects of the combination administration of Betosertib and T1-44 in a pancreatic cancer mouse model created by pancreatic cancer cell transplantation.

As a result of the study, when Betosertib and T1-44 were administered together, metastasis to surrounding tissues was reduced compared to T1-44 monotherapy, increasing the survival rate of mice by about 60%. Additionally, compared to T1-44 alone, the combination therapy with Betosertib significantly reduced tumor size. Furthermore, the combination treatment of Betosertib and T1-44 showed distinct changes in genes related to cancer cell migration ability, apoptosis processes, and extracellular matrix. In particular, the expression of BTG2, known as a tumor suppressor gene, was significantly increased with the combination therapy, the company explained.

A MedPacto official stated, "We confirmed in preclinical studies that the combination administration of Betosertib and T1-44 increases the expression of the tumor suppressor gene BTG2, thereby inhibiting pancreatic cancer metastasis and reducing tumor size."

AACR is an international cancer conference where about 20,000 researchers from over 120 countries gather annually to share cancer-related knowledge and clinical research. Along with the American Society of Clinical Oncology (ASCO) and the European Society for Medical Oncology (ESMO), it is considered one of the world's top three cancer conferences.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.